The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat

Joan T. Crofton; Leonard Share; Robert E. Shade; Won Jung Lee-Kwon; Maurice Manning; Wilbur H. Sawyer

doi:10.1161/01.HYP.1.1.31

The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat

Joan T. Crofton, Leonard Share, Robert E. Shade, Won Jung Lee-Kwon, Maurice Manning, Wilbur H. Sawyer

Research output: Contribution to journal › Article › peer-review

232 Scopus citations

Abstract

Experiments were performed to determine the role of vasopressin in deoxycorticosterone (DOC)-salt hypertension. In order to determine if vasopressin is necessary for the development of DOC-salt hypertension, rats with hereditary diabetes insipidus (DI) and normal Long-Evans rats (LE) were unilaterally nephrectomized, treated with DOC Pivalate (30 mg/kg, week) and given saline to drink for 8 weeks. A second group of DI rats were unilaterally nephrectomized, but received no treatment. Systolic blood pressure (SBP) increased 40 mm Hg in the LE group (p < 0.01) but failed to increase significantly in either DI group. Urinary excretion of vasopressin (UADH V) and SBP were measured in unilaterally nephrectomized LE rats treated with DOC and salt (DOC-LE), salt alone (NaCI-LE) and untreated rats (H₂O-LE). The U_ADHV was elevated in DOC-LE (p < 0.01) and NaCI-LE (p < 0.05) rats, but only the DOC-LE rats became hypertensive. Finally, the I.V. injection of analogs of vasopressin, which block its pressor but not antidluretic activity, lowered mean arterial blood pressure 27 ± 5 mm Hg in 11 conscious DOC-salt hypertensive rats. It is concluded that vasopressin plays a major role as a pressor agent in both the onset and maintenance of DOC-salt hypertension.

Original language	English (US)
Pages (from-to)	31-38
Number of pages	8
Journal	Hypertension
Volume	1
Issue number	1
DOIs	https://doi.org/10.1161/01.HYP.1.1.31
State	Published - Jan 1979

Keywords

Antidiuretic hormone Brattleboro rat
Diabetes insipidus
Doc-salt hypertension
Vasopressin
Vasopressin competitive inhibitor

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1161/01.HYP.1.1.31

Fingerprint Dive into the research topics of 'The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat'. Together they form a unique fingerprint.

Cite this

@article{341d5ba0f195488ba5b16f9840c225ba,

title = "The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat",

abstract = "Experiments were performed to determine the role of vasopressin in deoxycorticosterone (DOC)-salt hypertension. In order to determine if vasopressin is necessary for the development of DOC-salt hypertension, rats with hereditary diabetes insipidus (DI) and normal Long-Evans rats (LE) were unilaterally nephrectomized, treated with DOC Pivalate (30 mg/kg, week) and given saline to drink for 8 weeks. A second group of DI rats were unilaterally nephrectomized, but received no treatment. Systolic blood pressure (SBP) increased 40 mm Hg in the LE group (p < 0.01) but failed to increase significantly in either DI group. Urinary excretion of vasopressin (UADH V) and SBP were measured in unilaterally nephrectomized LE rats treated with DOC and salt (DOC-LE), salt alone (NaCI-LE) and untreated rats (H2O-LE). The UADHV was elevated in DOC-LE (p < 0.01) and NaCI-LE (p < 0.05) rats, but only the DOC-LE rats became hypertensive. Finally, the I.V. injection of analogs of vasopressin, which block its pressor but not antidluretic activity, lowered mean arterial blood pressure 27 ± 5 mm Hg in 11 conscious DOC-salt hypertensive rats. It is concluded that vasopressin plays a major role as a pressor agent in both the onset and maintenance of DOC-salt hypertension.",

keywords = "Antidiuretic hormone Brattleboro rat, Diabetes insipidus, Doc-salt hypertension, Vasopressin, Vasopressin competitive inhibitor",

author = "Crofton, {Joan T.} and Leonard Share and Shade, {Robert E.} and Lee-Kwon, {Won Jung} and Maurice Manning and Sawyer, {Wilbur H.}",

year = "1979",

month = jan,

doi = "10.1161/01.HYP.1.1.31",

language = "English (US)",

volume = "1",

pages = "31--38",

journal = "Hypertension",

issn = "0194-911X",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat

AU - Crofton, Joan T.

AU - Share, Leonard

AU - Shade, Robert E.

AU - Lee-Kwon, Won Jung

AU - Manning, Maurice

AU - Sawyer, Wilbur H.

PY - 1979/1

Y1 - 1979/1

N2 - Experiments were performed to determine the role of vasopressin in deoxycorticosterone (DOC)-salt hypertension. In order to determine if vasopressin is necessary for the development of DOC-salt hypertension, rats with hereditary diabetes insipidus (DI) and normal Long-Evans rats (LE) were unilaterally nephrectomized, treated with DOC Pivalate (30 mg/kg, week) and given saline to drink for 8 weeks. A second group of DI rats were unilaterally nephrectomized, but received no treatment. Systolic blood pressure (SBP) increased 40 mm Hg in the LE group (p < 0.01) but failed to increase significantly in either DI group. Urinary excretion of vasopressin (UADH V) and SBP were measured in unilaterally nephrectomized LE rats treated with DOC and salt (DOC-LE), salt alone (NaCI-LE) and untreated rats (H2O-LE). The UADHV was elevated in DOC-LE (p < 0.01) and NaCI-LE (p < 0.05) rats, but only the DOC-LE rats became hypertensive. Finally, the I.V. injection of analogs of vasopressin, which block its pressor but not antidluretic activity, lowered mean arterial blood pressure 27 ± 5 mm Hg in 11 conscious DOC-salt hypertensive rats. It is concluded that vasopressin plays a major role as a pressor agent in both the onset and maintenance of DOC-salt hypertension.

AB - Experiments were performed to determine the role of vasopressin in deoxycorticosterone (DOC)-salt hypertension. In order to determine if vasopressin is necessary for the development of DOC-salt hypertension, rats with hereditary diabetes insipidus (DI) and normal Long-Evans rats (LE) were unilaterally nephrectomized, treated with DOC Pivalate (30 mg/kg, week) and given saline to drink for 8 weeks. A second group of DI rats were unilaterally nephrectomized, but received no treatment. Systolic blood pressure (SBP) increased 40 mm Hg in the LE group (p < 0.01) but failed to increase significantly in either DI group. Urinary excretion of vasopressin (UADH V) and SBP were measured in unilaterally nephrectomized LE rats treated with DOC and salt (DOC-LE), salt alone (NaCI-LE) and untreated rats (H2O-LE). The UADHV was elevated in DOC-LE (p < 0.01) and NaCI-LE (p < 0.05) rats, but only the DOC-LE rats became hypertensive. Finally, the I.V. injection of analogs of vasopressin, which block its pressor but not antidluretic activity, lowered mean arterial blood pressure 27 ± 5 mm Hg in 11 conscious DOC-salt hypertensive rats. It is concluded that vasopressin plays a major role as a pressor agent in both the onset and maintenance of DOC-salt hypertension.

KW - Antidiuretic hormone Brattleboro rat

KW - Diabetes insipidus

KW - Doc-salt hypertension

KW - Vasopressin

KW - Vasopressin competitive inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0018288301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018288301&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.1.1.31

DO - 10.1161/01.HYP.1.1.31

M3 - Article

C2 - 544512

AN - SCOPUS:0018288301

VL - 1

SP - 31

EP - 38

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -